Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy
Authors: Anthony M Magliocco, Jennifer Moughan, David T Miyamoto, Jeff Simko, William U Shipley, Phillip J Gray, Michael P Hagan, Matthew Parliament, William J Tester, Anthony L Zietman, Susan McCarthy, Daryoush Saeed-Vafa, Yin Xiong, Taylor Ayral, Alan C Hartford, Ashish Patel, Seth A Rosenthal, Susan Chafe, Richard Greenberg, Michael A Schwartz, Mark E Augspurger, John A Keech, Kathryn A Winter, Felix Y Feng, Jason A Efstathiou
Journal: JAMA Network Open | Volume 5, Issue 11
Publisher: American Medical Association
Importance:
Bladder-preserving trimodality therapy can be an effective alternative to radical cystectomy for treatment of muscle-invasive bladder cancer (MIBC), but biomarkers are needed to guide optimal patient selection. The DNA repair protein MRE11 is a candidate response biomarker that has not been validated in prospective cohorts using standardized measurement approaches.
Objective:
To evaluate MRE11 expression as a prognostic biomarker in MIBC patients receiving trimodality therapy using automated quantitative image analysis.